FSK's Shrink-to-Grow Strategy: KKR Backs a Turnaround at a Deep Discount to NAV

Strategic Backstop in Motion

FS KKR Capital Corp. (FSK) is executing a carefully choreographed shrinking act. On Q2 2026 earnings, management touted progress on the portfolio rotation initiatives first laid out in May: KKR's $150 million tender closed, a $150 million convertible preferred investment settled, and a $300 million buyback program is underway. The adviser also began a four-quarter waiver of its subordinated income incentive fee, a direct distribution level support move. As CFO Steven Lilly put it on the call, “we reduced leverage and returned net debt-to-equity to our target range of 1 to 1.25x” — Steven Lilly, Head of Portfolio Management · 2026-08-06, while available liquidity sits at $3.5 billion. The stock has responded—up 17.6% over the past 90 days—though it still trades at roughly a 55% discount to book.

Investors are right to demand proof, and management delivered some tangible data points. Buyback activity accelerated: ~$4 million repurchased in Q2, plus $36 million in July/August, bringing cumulative repurchases to $40 million at an average $10.73. That is still a drip relative to the $300 million authorization, but as CEO Dan Pietrzak noted, the pace is deliberate: “we will be mindful about liquidity and leverage as we think about the share repurchase, but we do have an intention to fulfill that” — Daniel Pietrzak, Chief Executive Officer · 2026-08-06.

Markdowns and Non-Accruals Still Biting

The portfolio is clearly in a repair phase. NAV per share fell 2.8% in Q2 to $18.30, despite earning $0.44 of net investment income, because valuation losses on a handful of legacy names—PRG, ATX, Wittur, Peraton, Lionbridge, and Medallia—drove nearly the entire markdown. Net income has swung to a loss on a GAAP basis, and the company now trades at a price-to-book of 0.5x, down from 0.9x a year ago. Management points to active work on each name, but the path is long.

The non-accrual list tells a mixed story: two new names (Heniff, Alacrity, ~$104M cost) were added, while two (Dental Care Alliance, Affordable Care) were removed after restructurings. Non-accruals now represent 7.1% of portfolio cost (down from 8.1%) and 3.8% of fair value (down from 4.2%). Pietrzak struck a realistic tone:

As we execute on the remaining portion of our common stock buyback program and continue to improve the quality of our investment portfolio, we do acknowledge that FSK will become a smaller fund. On the other side of the equation, we anticipate it will be a higher-quality fund as well.

Smaller but Tighter

The shrinking is intentional, and the debt to equity ratio is the anchor. Gross and net leverage dropped to 127% and 122% respectively, down from 138%/131% in Q1. Management targets the middle of the 1.0–1.25x range over time, and they are actively rotating out of lower-yielding assets. $500 million of loans were sold to third parties in Q2 at prices in line with Q1 marks, and the joint-venture stake – now 79% owned by FSK – remains a modest 14% of portfolio fair value, a lever they can use to fund buybacks without raising leverage.

The company claims the upper end of the middle market remains resilient, citing median portfolio company EBITDA of $130M and interest coverage of 1.9x. However, the forward guidance of 8–9% annualized NII on NAV is below the 9.6% achieved in Q2, a sign that the earnings power is still under pressure from lower yields, portfolio shrinkage, and the non-accrual drag. As Pietrzak said on the May call, “we have been active, and there's been some pretty good demand for us trimming some of the taller trees or some of the larger names of the portfolios” — Daniel Pietrzak, Chief Investment Officer · 2026-05-11—a theme that has now turned into a full-scale strategy.

What makes the story compelling is the unusual level of adviser support. The fee waiver alone added $11M to Q2 NII, and the convertible preferred (paying 5% cash or 7% PIK, escalating after five years) provides a capital buffer without diluting common shareholders. That said, the company acknowledges the next steps depend on repayments picking up—which have been muted—and on the broader M&A market reviving. If that turns, the excess liquidity can fund more buybacks and portfolio deleveraging; if not, FSK may need to lean on its JV or risk further NAV erosion.

In summary, FSK is a classic restructuring story: a well-capitalized sponsor (KKR) throwing its weight behind a fund that has lost market confidence, trading at half of book, with a clear plan to shrink into a tighter, higher-quality portfolio. The recent stock rally suggests investors are starting to believe, but the fundamental data—net income on a trailing basis is negative, and NAV is still declining—reminds us that the market has not yet forgiven the legacy missteps. The next two quarters will be crucial to see if the buyback effort and non-accrual resolutions can actually move the needle on per-share earnings power.